- Generic name
- Etoricoxib
- Strength
- 90 mg
- Dosage form
- Tablet
- Manufactured by
- United Chemicals & Pharmaceuticals Ltd.
Espana 90 Tablet
About Espana 90 Tablet
The tablet Espana 90 contains Etoricoxib and is made by United Chemicals & Pharmaceuticals Ltd. It does not treat the underlying disease; it relieves symptoms.
There are 90 brands of Etoricoxib listed in Bangladesh. The lowest listed price is Retoz 90 mg Tablet at ৳ 1 per unit.
What is Espana 90 Tablet?
The tablet Espana 90 contains Etoricoxib and is made by United Chemicals & Pharmaceuticals Ltd. Because it is a prescription medicine, the doctor decides whether it suits you and how it should be taken. Medicines in this group are used to relieve symptoms such as pain and inflammation in a number of joint and muscle conditions. Ask your doctor or pharmacist if you are unsure about it.
Uses of Espana 90
It does not treat the underlying disease; it relieves symptoms. Espana 90 is used for symptomatic relief in several painful and inflammatory conditions. It reduces pain and inflammation. Ask your doctor whether it is right for your condition.
How to use Espana 90
Swallow the tablet with water, as advised. Espana 90 is taken by mouth. If you are unsure how to take it, ask your doctor or pharmacist. The doctor decides the dose and how long you take it, based on your condition and health. Do not change the dose or stop on your own.
Side effects of Espana 90
Less common effects include dry mouth, taste changes, mouth ulcers, appetite or weight change, chest pain, flushing, cough, shortness of breath, nosebleeds, anxiety, reduced mental alertness, tingling, electrolyte disturbance, muscle aches and joint pain. Rarely, confusion and hallucinations may occur. Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any effect troubles you.
Safety and precautions
People with active stomach ulcers or gastrointestinal bleeding, severe liver or kidney problems, heart failure, inflammatory bowel disease, or a history of allergic reactions to aspirin or NSAIDs should not take it. Espana 90 90 mg tablet is not recommended during pregnancy or breastfeeding. Elderly people and those with stomach, heart or kidney risk factors need careful assessment. Keep out of reach of children.
Frequently asked questions
What does Espana 90 treat?
It does not treat the underlying disease; it relieves symptoms. Espana 90 is used for symptomatic relief in several painful and inflammatory conditions.
How do I use Espana 90 correctly?
Swallow the tablet with water, as advised. Espana 90 is taken by mouth.
What are the side effects of Espana 90?
Less common effects include dry mouth, taste changes, mouth ulcers, appetite or weight change, chest pain, flushing, cough, shortness of breath, nosebleeds, anxiety, reduced mental alertness, tingling, electrolyte disturbance, muscle aches and joint pain. Rarely, confusion and hallucinations may occur.
Who should be careful with Espana 90?
People with active stomach ulcers or gastrointestinal bleeding, severe liver or kidney problems, heart failure, inflammatory bowel disease, or a history of allergic reactions to aspirin or NSAIDs should not take it. Espana 90 90 mg tablet is not recommended during pregnancy or breastfeeding.
Indications
- Osteoarthritis (OA)
- Rheumatoid arthritis (RA)
- Ankylosing spondylitis, and
- The pain and signs of inflammation associated with acute gouty arthritis.
- For the short-term treatment of moderate pain associated with dental surgery.
Pharmacology
Dosage & Administration
- Osteoarthritis: The recommended dose is 30 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy.
- Rheumatoid arthritis: The recommended dose is 90 mg once daily.
- Ankylosing spondylitis: The recommended dose is 90 mg once daily.
- Acute gouty arthritis: The recommended dose is 120 mg once daily. In clinical trials for acute gouty arthritis, Etoricoxib was given for 8 days.
- Postoperative dental surgery pain: The recommended dose is 90 mg once daily, limited to a maximum of 3 days.
Interaction
- Oral anticoagulants: In subjects stabilized on chronic warfarin therapy, the administration of Etoricoxib was associated with an increase in prothrombin time.
- Diuretics, ACE inhibitors and Angiotensin II Antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs.
- Acetylsalicylic Acid: Etoricoxib can be used concomitantly with acetylsalicylic acid at doses used for cardiovascular prophylaxis (low-dose acetylsalicylic acid).
- Ciclosporin and tacrolimus: Although this interaction has not been studied with Etoricoxib, coadministration of ciclosporin or tacrolimus with any NSAID may increase the nephrotoxic effect of ciclosporin or tacrolimus.
- Lithium: NSAIDs decrease lithium renal excretion and therefore increase lithium plasma levels.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
- Active peptic ulceration or active gastro-intestinai (Gl) bleeding.
- Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.
- Pregnancy and lactation.
- Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score 10).
- Estimated renal creatinine clearance <30 ml/min.
- Children and adolescents under 16 years of age.
- Inflammatory bowel disease.
- Congestive heart failure (NYHA ll-IV).
- Patients with hypertension whose blood pressure is persistently elevated above 140/90 mmHg and has not been adequately controlled.
- Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.
Side Effects
Pregnancy & Lactation
Precautions & Warnings
- Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly or patients with a prior history of gastrointestinal disease, such as ulceration and Gl bleeding.
- Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with Etoricoxib after careful consideration.
- Administration of Etoricoxib may cause a reduction in prostaglandin formation and, secondarily, in renal blood flow, and thereby impair renal function. Monitoring of renal function in such patients should be considered.
- Caution should be exercised in patients with a history of cardiac failure, left ventricular dysfunction, or hypertension and in patients with pre-existing edema from any other reason.
- Any patients with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormalliver function test has occurred, should be monitored. If signs of hepatic insufficiency occur, or if persistently abnormal liver function tests (three times the upper limit of normal) are detected, Etoricoxib should be discontinued.
- Etoricoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.
- Etoricoxib may mask fever and other signs of inflammation. Caution should be exercised when co-administering Etoricoxib with warfarin or other oral anticoagulants.
Overdose Effects
Storage Conditions
Alternative brands of Etoricoxib
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.